NKG2D公司
免疫疗法
CD16
癌症免疫疗法
嵌合抗原受体
自然杀伤细胞
医学
抗原
免疫学
癌症研究
免疫系统
生物
细胞毒性
CD8型
CD3型
体外
生物化学
作者
Shee Kwan Phung,Jeffrey S. Miller,Martin Felices
标识
DOI:10.1007/s40291-021-00550-6
摘要
Natural killer (NK) cell-mediated cancer immunotherapy has grown significantly over the past two decades. More recently, multi-specific engagers have been developed as cancer therapeutics to effectively arm endogenous NK cells to more potently induce specific cytolytic responses against tumor targets. This review explores the bi- and tri-specific NK/tumor engagers that are emerging as a new generation of immunotherapeutics. These molecules vary in configuration, but they typically have small molecular weights and domains that engage specific tumor antigens and NK cell-activating receptors such as CD16, NKp30, NKp46, and NKG2D. They have demonstrated compelling potential in boosting NK cell cytotoxicity against specific tumor targets. This highly adaptable off-the-shelf platform, which in some formats also integrates cytokines, is poised to revolutionize targeted NK cell immunotherapy, either as a monotherapy or in combination with other effective anti-cancer therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI